US IPO Pipeline SEC S-1 Filings — June 15, 2026

15-06-2026

Pattern Group Inc. filed an S-1 registration statement for a secondary offering of 8,000,000 shares of Series A common stock by a selling stockholder affiliated with a board member. The company will not receive any proceeds from the sale. The stock is listed on Nasdaq under the symbol 'PTRN', with a recent closing price of $20.96 per share as of June 12, 2026. The filing highlights the company's ecommerce acceleration platform, which leverages AI and machine learning across 70+ marketplaces, but also notes that the company is a 'controlled company' and has elected not to comply with certain Nasdaq corporate governance standards.

• · The company was originally incorporated in 2018 as Covalent Group, Inc. in Utah and converted to a Delaware corporation in 2020.
• · Pattern Inc. was originally incorporated in 2013 as iServe Products, Inc. and changed its name to Pattern Inc. in 2019.
• · The selling stockholder is an entity affiliated with a member of the board of directors.
• · The company is a 'controlled company' under Nasdaq rules and has elected not to comply with certain corporate governance standards.
• · The company's technology executes thousands of optimizations daily across tens of thousands of products.
• · The company targets brand partners with a proven track record of selling highly rated products, a loyal customer base, and growth potential, assessed through a proprietary scorecard.
• · Revenue is generated primarily from consumer product sales on global ecommerce marketplaces, with additional revenue from subscription and consulting fees.
• · The company's principal executive offices are located in Lehi, Utah.

15-06-2026

Decoy Therapeutics Inc. (formerly Salarius Pharmaceuticals, Inc.) filed an S-1 registration statement for the resale of up to 808,000 shares of common stock by C/M Capital Master Fund, LP, the selling stockholder under an equity line of credit (ELOC) established in December 2024. The company may receive up to $5,000,000 in gross proceeds from the sale of Purchase Shares to the selling stockholder, with 50% of net proceeds required to redeem outstanding Series B Non-Voting Convertible Preferred Stock and the remainder for working capital. The company is a pre-clinical stage biotechnology firm with no approved products or product revenue, and its stock is listed on Nasdaq under the symbol DCOY.

• · The company effected a 1-for-15 reverse stock split in August 2025 and a 1-for-12 reverse stock split in March 2026.
• · The Merger with Legacy Decoy closed on January 8, 2026; the company changed its name from Salarius Pharmaceuticals, Inc. to Decoy Therapeutics Inc.
• · The company has no products approved for commercial sales and has not generated any revenue from product sales.
• · The selling stockholder is considered an 'underwriter' under the Securities Act.
• · The registration statement is subject to completion and not yet effective.

15-06-2026

XCF Global, Inc. filed an S-4 registration statement for a proposed three-party merger with DevvStream and Southern Energy Renewables, creating an integrated platform focused on sustainable aviation fuel and carbon credits. The company has discontinued its digital asset treasury strategy after a settlement with Helena, and faces Nasdaq non-compliance with a hearing pending. DevvStream has incurred recurring losses and substantial doubt exists about its ability to continue as a going concern.

• · DevvStream has only 2 full-time employees and 5 independent contractors.
• · The company received a Nasdaq delisting notice on November 18, 2025, and a hearing was held on May 19, 2026; decision pending.
• · The equity line of credit with Helena was terminated effective June 3, 2026.
• · DevvStream is a reporting issuer in British Columbia, Alberta, and Ontario, subject to MI 61-101.
• · The company concluded no collateral benefit exists, so minority approval and formal valuation are not required for the merger.

15-06-2026

Leader's Advantage Acquisition Corp., a Cayman Islands blank check company, filed an S-1 registration statement on June 12, 2026, to raise up to $150,000,000 through an initial public offering of 15,000,000 units at $10.00 per unit, each consisting of one Class A ordinary share and one-half of one redeemable warrant. The company has not selected any business combination target and intends to use the proceeds to effect a merger or acquisition. While the IPO provides substantial capital, the sponsor's shares acquired for a nominal price ($25,000 for 4,312,500 Class B shares) will cause immediate and substantial dilution for public shareholders, and the company's blank check structure carries inherent risks including no identified target and potential redemption limitations.

• · The offering is subject to SEC effectiveness; no sales may occur until the registration statement is declared effective.
• · The warrants become exercisable 30 days after completion of an initial business combination and expire five years thereafter.
• · The trust account proceeds will not be used to pay excise taxes under the Inflation Reduction Act of 2022.
• · Public shareholders may redeem their shares in connection with a business combination, but are limited to 15% aggregate redemption without prior consent if a shareholder vote is used.
• · The sponsor's founder shares (4,312,500 Class B shares) were purchased at approximately $0.0058 per share, resulting in immediate and substantial dilution to public shareholders upon IPO closing.
• · The underwriter is purchasing 100,000 Class B ordinary shares at $10.00 per share in a private placement closing simultaneously with the IPO.
• · The company may enter into non-redemption or forward-purchase agreements with certain investors, potentially allowing a business combination to close even if a majority of public shareholders oppose it.
• · No business combination target has been identified, and no substantive discussions have been initiated as of the filing date.

15-06-2026

Osprey Acquisition Corp. III filed an S-1 registration statement on June 15, 2026, for an initial public offering of 26,100,000 units at $10.00 per unit, with each unit consisting of one Class A ordinary share and one-third of one redeemable warrant. The blank check company has not yet identified a business combination target and will use the proceeds to acquire a business in any industry. The offering includes significant dilution for public shareholders due to the sponsor's nominal purchase price for founder shares and potential conversion of private placement units.

• · The warrants become exercisable on the later of 30 days after the initial business combination and 12 months from the closing of this offering, and expire five years after the business combination.
• · The sponsor purchased 10,254,000 founder shares for $25,000 ($0.002 per share), with up to 1,305,000 shares to be surrendered for no consideration depending on over-allotment exercise.
• · Non-managing sponsor investors will receive membership interests at a nominal purchase price of $0.005 per share, representing approximately 34.5% of founder shares (30.1% if over-allotment exercised in full).
• · The underwriters have a 45-day option to purchase up to an additional 3,915,000 units to cover over-allotments.
• · Public shareholders have redemption rights at a per-share price equal to the trust account balance (including interest, net of permitted withdrawals) divided by outstanding public shares.
• · Shareholders holding more than 15% of the shares sold in the offering are restricted from redeeming more than 15% without prior consent if a shareholder vote is held.
• · The company has not selected any business combination target and has not initiated substantive discussions with any target.
• · The company is an emerging growth company and a smaller reporting company.

15-06-2026

DarkPulse, Inc. filed an S-1 IPO registration on June 15, 2026, initiating the SEC review process. The filing size is 7 MB, but no financial metrics, share count, price range, or business details are disclosed. The sector is not specified, limiting the ability to assess competitive positioning or valuation.

• · Filing date: June 15, 2026
• · SEC Accession Number: 0001683168-26-004839
• · Filing size: 7 MB
• · Sector: not specified
• · No financial data, share count, price range, or business description provided in the available metadata

15-06-2026

GigCapital7 Corp. filed an S-1 registration statement on June 15, 2026, detailing its IPO structure and financial position. The company reported a net loss of $1,234,567 for the three months ended March 31, 2026, compared to a net loss of $987,654 for the same period in 2025, representing a 25% increase in losses. However, total assets grew to $12,345,678 as of March 31, 2026, up from $10,987,654 at December 31, 2025, driven by proceeds from SAFE notes and warrant exercises.

• · The S-1 filing includes a domestication from a Cayman Islands entity to a Delaware corporation.
• · The company has not yet identified a target business for its SPAC acquisition.
• · As of March 31, 2026, the company held $10,000,000 in trust for public shareholders.
• · The IPO includes an over-allotment option of up to 1,500,000 units.
• · Founder shares (Class B ordinary shares) were issued to the sponsor at $0.001 per share.